27. Si HB, Zeng Y, Shen B et al: The influence of body mass index on the outcomes of primary total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc 2015; 23: 1824. 28. Kunutsor SK, Whitehouse MR, Blom AW et al: Patient related risk factors for periprosthetic joint infection after total joint arthroplasty: a systematic review and meta analysis. PLoS One 2016; 11:e0150866. 29. Suskind AM, Walter LC, Jin C et al: Impact of frailty on complications in patients undergoing common urological procedures: a study from the American College of Surgeons National Surgical Quality Improvement database. BJU Int 2016; 117: 836. 30. Lascano D, Pak JS, Kates M et al: Validation of a frailty index in patients undergoing curative surgery for urologic malignancy and comparison with other risk stratification tools. Urol Onc 2015; 33: e1. 31. Patel HD, Ball MW, Cohen JE et al: Morbidity of urologic surgical procedures: an analysis of rates, risk factors, and outcomes. Urology 2015; 85: 552. 32. Sanda MG, Dunn RL, Michalski J et al: Quality of life and satisfaction with outcome among prostate cancer survivors. N Engl J Med 2008; 358:1250. 33. Montgomery JS, Gayed BA, Hollenbeck BK et al: Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy. J Urol 2006;176: 257. 34. Mitchell JM: Urologists use of intensity modulated radiation therapy for prostate cancer. N Engl J Med 2013; 369: 1629. 35. Fowler FJ Jr., McNaughton Collins M, Albertsen PC et al: Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 2000; 283: 3217. 36. Tyson MD, Graves AJ, O’Neil B et al: Urologist level correlation in the use of observation for low and high risk prostate cancer. JAMA Surg 2017; 152: 27. 37. Aizer AA, Paly JJ and Efstathiou JA. Multidisciplinary care and management selection in prostate cancer. Semin Radiat Oncol 2013;23:157. 38. Valicenti RK, Gomella LG, El Gabry EA et al: The multidisciplinary clinic approach to prostate cancer counseling and treatment. Semin Urol Oncol 2000; 18:188. 39. Gomella LG: Prostate cancer: the benefits of multidisciplinary prostate cancer care. Nat Rev Urol 2012;9:360. 40. Jang TL, Bekelman JE, Liu Y et al: Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 2010; 170: 440. 41. Donovan JL, Hamdy FC, Lane JA et al: Patient reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016; 375:1425. 42. van den Bergh RC, Essink Bot ML, Roobol MJ et al: Anxiety and distress during active surveillance for early prostate cancer. Cancer 2009; 115:3868. 43. Barocas DA, Alvarez J, Resnick MJ et al: Association between radiation therapy, surgery, American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Copyright © 2017 American Urological Association Education and Research, Inc.® Clinically Localized Prostate Cancer 43 or observation for localized prostate cancer and patient reported outcomes after 3 years. JAMA 2017; 317: 1126. 44. Chen RC, Basak R, Meyer AM et al: Association between radical prostatectomy, external beam radiotherapy, brachytherapy, or active surveillance and patient reported quality of life among men with localized prostate cancer. JAMA 2017; 317: 1141. 45. Fujita K, Landis P, McNeil BK et al: Serial prostate biopsies are associated with an increased risk of erectile dysfunction in men with prostate cancer on active surveillance. J Urol 2009;182:2664. 46. Hilton JF, Blaschko SD, Whitson JM et al: The impact of serial prostate biopsies on sexual function in men on active surveillance for prostate cancer. J Urol 2012; 188:1252. 47. Steineck G, Helgesen F, Adolfsson J et al: Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347:790. 48. Bokhorst LP, Valdagni R, Rannikko A et al: A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol 2016; 70:954. 49. Loeb S, Folkvaljon Y, Makarov DV et al: Five year nationwide follow up study of active surveillance for prostate cancer. Eur Urol 2015; 67:233. 50. Hamdy FC, Donovan JL, Lane JA et al: 10 year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016; 375:1415. 51. Wilt TJ, Brawer MK, Jones KM: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367:203. 52. Donovan JL, Hamdy FC, Lane JA et al: ProtecT study group. Patient reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016; 375:1425. 53. Resnick MJ, Koyama T, Fan KH et al: Long term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013; 368:436. 54. Nam RK, Cheung P, Herschorn S et al: Incidence of complications other than urinary incontinence or erectile dyscunction after radical prostatectomy or radiotherapy for prostate cancer: a population based cohort study. Lancet Oncol 2014; 15: 223. 55. Murray L, Henry A, Hoskin P et al: Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique. Radiother Oncol 2014; 110; 213. 56. American Urological Association: Ten things physicians and patients should question. Choosing Wisely 2016. http://www.choosingwisely.org/societies/american urological association/ 57. American Society of Clinical Oncology: Ten things physicians and patietns should question. Choosing Wisely 2013. http://www.choosingwisely.org/societies/american society of clinical oncology/ 58. D'Amico AV, Chen MH, Renshaw AA et al: Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol 2008; 26: 2979. 59. Kibel AS, Ciezki JP, Klein EA et al: Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 2012; 187:1259. 60. Cooperberg MR, Vickers AJ, Broering JM et al: Comparative risk adjusted mortality outcomes after primary surgery, radiotherapy, or androgen deprivation therapy for localized prostate cancer. Cancer 2010; 116: 5226. 61. Marina O, Gustafson GS, Kestin LL, Brabbins DS, Chen PY, Ye H, Martinez AA, Ghilezan MI, Wallace M, Krauss DJ. Comparison of dose escalated, image guided radiotherapy vs. dose escalated, high dose rate brachytherapy boost in a modern cohort of intermediate risk prostate cancer patients. Brachytherapy 2014; 13:59. 62. Eggener SE, Scardino PT, Walsh PC et al: Predicting 15 year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869. 63. Ross HM, Kryvenko ON, Cowan JE et al: Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol 2012;36:1346. 64. Kasperzyk JL, Shappley WV 3rd, Kenfield SA et al: Watchful waiting and quality of life among American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Copyright © 2017 American Urological Association Education and Research, Inc.® Clinically Localized Prostate Cancer 44 prostate cancer survivors in the Physicians’ Health Study. J Urol 2011; 186: 1862. 65. Shappley WV 3rd, Kenfield SA, Kasperzyk JL et al: Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009; 27: 4980. 66. Klotz L, Vesprini D, Sethukavalan P et al: Long term follow up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015; 33:272. 67. Macleod LC, Ellis WJ, Newcomb LF et al: Timing of adverse prostate cancer reclassification on first surveillance biopsy: results from the Canary Prostate Cancer Active Surveillance Study. J Urol 2016; Epub ahead of print. 68. Newcomb LF, Thompson IM Jr., Boyer HD et al: Outcomes of active surveillance for the management of clinically localized prostate cancer in the prospective, multi institutional Canary PASS cohort. J Urol 2016; 195:313. 69. Corcoran NM, Casey RG, Hong MK et al: The ability of prostate specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU Int 2012; 110: 36. 70. San Francisco IF, Werner L, Regan MM et al: Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 2011; 185: 471. 71. Bhindi B, Kulkarni GS, Finelli A et al: Obesity is associated with risk of progression for low risk prostate cancers managed expectantly. Eur Urol 2014; 66: 841. 72. Ploussard G, de la Taille A, Bayoud Y et al: The risk of upstaged disease increases with body mass index in low risk prostate cancer patients eligible for active surveillance. Eur Urol 2012; 61: 356. 73. Sundi D, Faisal FA, Trock BJ et al: Reclassification rates are higher among African American men than Caucasians on active surveillance. Urology 2015; 2015. 85:155. 74. Sundi, D, Ross AE, Humphreys EB et al: African American men with very low risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol 2013; 31:2991. 75. Jones CU, Hunt D, McGowan DG et al: Radiotherapy and short term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365:107. 76. Donnelly BJ, Saliken JC, Brasher PM et al: A randomized trial of external beam radiotherapy versus cryoablation in patients with localized prostate cancer. Cancer 2010; 116:323. 77. Langenhuijsen JF, Broers EMP and Vergunst H: Cryosurgery for prostate cancer: an update on clinical results of modern cryotechnology. Eur Urol 2009; 55:76. 78. Lukka H, Waldron T, Chin J et al: High intensity focused ultrasound for prostate cancer: a systematic review. Clin Oncol 2011; 23: 117. 79. Schroder FH, Hugosson J, Roobol MJ et al: Prostate cancer mortality at 11 years of follow up. N Engl J Med 2012; 366: 981. 80. Sammon JD, Abdollah F, Reznor G et al: Patterns of declining use and the adverse effect of primary androgen deprivation on all cause mortality in elderly men with prostate cancer. Eur Urol 2015; 68: 32. 81. Karnes RJ, Bergstralh EJ, Davicioni E et al” Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013; 190:2047. 82. Klein EA, Yousefi K, Haddad Z et al: A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node negative high risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol 2015; 67:778. 83. Ross AE, Johnson MH, Yousefi K et al: Tissue based genomics augments post prostatectomy risk stratification in a natural history cohort of intermediate and high risk men. Eur Urol 2016; 69:157. 84. Klein EA, Haddad Z, Yousefi K et al: Decipher genomic classifier measured on prostate biopsy predicts metastasis risk. Urology 2016;90:148. American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Copyright © 2017 American Urological Association Education and Research, Inc.® Clinically Localized Prostate Cancer 45 85. Nguyen PL, Martin NE, Choeurng V et al: Utilization of biopsy based genomic classifier to predict distant metastasis after definitive radiation and short course ADT for intermediate and high risk prostate cancer. Prostate Cancer Prostatic Dis 2017; Epub ahead of print. 86. Klein EA, Cooperberg MR, Magi Galluzzi C et al: A 17 gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol 2014; 66:550. 87. Cullen J, Rosner IL, Brand TC et al: A biopsy based 17 gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low and intermediate risk prostate cancer. Eur Urol 2015; 68:123. 88. Brand TC, Zhang N, Crager MR et al: Patient specific meta analysis of 2 clinical validation studies to predict pathologic outcomes in prostate cancer using the 17 gene genomic prostate score. Urology 2016; 89:69. 89. Cuzick J, Berney DM, Fisher G et al: Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012; 106:1095. 90. Cuzick J, Stone S, Fisher G et al: Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. Br J Cancer 2015; 113:382. 91. Sartor O, Eisenberger M, Kattan MW et al: Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist 2013; 18: 549. 92. Eberhardt SC, Carter S, Casalino DD et al: ACR Appropriateness Criteria prostate cancer—pretreatment detection, staging, and surveillance. J Am Coll Radiol 2013; 10: 83. 93. Hedge JV, Mulkern RV, Panych LP et al: Multiparametric MRI of prostate cancer: an update on state of the art technique and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging. 37: 1035. 94. Conde Moreno AJ, Herrando Parreño G, Muelas Soria R et al: Whole body diffusion weighted magnetic resonance imaging (WB DW MRI) vs choline positron emission tomography computed tomography (choline PET/CT) for selecting treatments in recurrent prostate cancer. Clin Transl Oncol 2016; Epub ahead of print. 95. Barrio M, Fendler WP, Czernin J et al: Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Rev Mol Diagn 2016; 16: 1177. 96. Bill Axelson A, Holmberg L, Ruutu M, et al: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708. 97. Paulson DF, Lin GH, Hinshaw W et al: Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982; 128:502. 98. Tewari A, Divine G, Chang P et al: Long term survival in men with high grade prostate cancer: a comparison between conservative treatment, radiation therapy and radical prostatectomy a propensity scoring approach. J Urol 2007; 177:911. 99. Albertsen PC, Hanley JA, Penson DF et al: 13 year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol 2007;177:932. 100. Merglen A, Schmidlin F, Fioretta G et al: Short and long term mortality with localized prostate cancer. Arch Intern Med 2007; 167:1944. 101. Zelefsky MJ, Eastham JA, Cronin AM et al: Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010; 28:1508. 102. Abdollah F, Schmitges J, Sun M et al: Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population based analysis. Int J Urol 2012; 19:836. 103. Hoffman RM, Koyama T, Fan KH et al: Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst 2013; 105:711. 104. Lee JY, Cho KS, Kwon JK et al: A competing risk analysis of cancer specific mortality of initial treatment with radical prostatectomy versus American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Copyright © 2017 American Urological Association Education and Research, Inc.® Clinically Localized Prostate Cancer 46 radiation therapy in clinically localized high risk prostate cancer. Ann Surg Oncol 2014; 21:4026. 105. Sooriakumaran P, Nyberg T, Akre O et al: Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 2014; 348: g1502. 106. Degroot JM, Brundage MD, Lam M et al: Prostate cancer specific survival differences in patients treated by radical prostatectomy versus curative radiotherapy. Can Urol Assoc J 2013; 7:E299. 107. Sun M, Sammon JD, Becker A et al: Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation. BJU Int 2014;113: 200. 108. Wallis CJ, Saskin R, Choo R et al: Surgery versus radiotherapy for clinically localized prostate cancer: a systematic review and meta analysis. Eur Urol 2016; 70:21. 109. D’Amico AV, Chen MH, Renshaw A et al: Long term follow up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA 2015; 314: 1291. 110. Al Mamgani A, van Putten WL, Heemsbergen WD et al: Update of Dutch multicenter dose escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 980. 111. Dearnaley DP, Jovic G, Syndikus I et al: Escalated dose versus control dose conformal radiotherapy for prostate cancer: long term results from the MRC RT01 randomised controlled trial. Lancet Oncol 2014; 15: 464. 112. Kuban DA, Tucker SL, Dong L et al: Long term results of the, M. D. Anderson randomized dose escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008; 70: 67. 113. Beckendorf V, Guerif S, Le Prise E et al: 70 Gy versus 80 Gy in localized prostate cancer: 5‑year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011; 80: 1056. 114. Bolla M, Maingon P, Carrie C et al: Short androgen suppression and radiation dose escalation for intermediate and high risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol 2016; 34: 1748. 115. Babaian RJ, Donnelly B, Bahn D et al: Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 2008; 180:1993. 116. Cohen JK, Miller RJ Jr., Ahmed S et al: Ten year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 2008; 71:515. 117. Donnelly BJ, Saliken JC, Ernst DS et al: Prospective trial of cryosurgical ablation of the prostate: five year results. Urology 2002; 60:645. 118. van der Poel H, Klotz L, Andriole G et al: Role of active surveillance and focal therapy in low and intermediate risk prostate cancers. World J Urol 2015;33:907. 119. Huang CC, Kong MX, Zhou M et al: Gleason score 3 + 4=7 prostate cancer with minimal quantity of gleason pattern 4 on needle biopsy is associated with low risk tumor in radical prostatectomy specimen. Am J Surg Pathol 2014; 38:1096. 120. Kır G, Seneldir H and Gumus E: Outcomes of Gleason score 3 + 4 = 7 prostate cancer with minimal amounts (<) vs ≥ of Gleason pattern 4 tissue in needle biopsy specimens. Ann Diagn Pathol 2016; 20:48. 121. Prasad SM, Eggener SE, Lipsitz SR et al: Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. J Clin Oncol 2014; 32: 2471. 122. Truesdale MD, Cheetham PJ, Hruby GW et al: An evaluation of patient selection criteria on predicting progression free survival after primary focal unilateral nerve sparing cryoablation for prostate cancer: recommendations for followup. Cancer J 2010; 16:544. 123. Ahmed HU, Hindley RG, Dickinson L et al: Focal therapy for localized unifocal and multifocal prostate cancer: a prospective development study Lancet Oncol 2012; 13:622. 124. Valerio M, Ahmed HU, Emberton M et al: The role of focal therapy in the management of localized prostate cancer: a systematic review. Eur Urol 2014; 66:732. 125. Klotz L: Active surveillance and focal therapy for low intermediate risk prostate cancer. Transl Androl Urol 2015; 4:342. American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Copyright © 2017 American Urological Association Education and Research, Inc.® Clinically Localized Prostate Cancer 47 126. Wollin DA and Makarov DV: Guideline of guidelines: imaging of localized prostate cancer. BJU Int 2015; 116: 526. 127. Lin K, Szabo Z, Chin BB et al: The value of a baseline bone scan in patients with newly diagnosed prostate cancer. Clin Nucl Med 1999; 24: 579. 128. Merdan S, Womble PR, Miller DC et al: Toward better use of bone scans among men with early stage prostate cancer. Urology 2014; 84: 793. 129. Oesterling JE: Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. Urol Clin North Am 1993; 20: 705. 130. O’Dowd GJ, Veltri RW, Oroco R et al: Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol 1997; 158: 687. 131. Levran Z, Gonzalez JA, Diokno AC et al: Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? Br J Urol 1995; 75: 778. 132. Fox JJ, Schoder H and Larson SM: Molecular imaging of prostate cancer. Curr Opin Urol 2012; 22: 320. 133. Kelloff GJ, Hoffman JM, Johnson B et al: Progress and promise of FDG PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005; 11: 2785. 134. Bolla M, Collette L, Blank L et al: Long term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103. 135. Bolla M, de Reijke TM, Van Tienhoven G et al: Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516. 136. Horwitz EM, Bae K, Hanks GE at al: Ten year follow up of radiation therapy oncology group protocol 92 02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497. 137. Warde P, Mason M, Ding K et al: Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378: 2104. 138. Widmark A, Klepp O, Solberg A et al: Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG 7/SFUO 3): an open randomised phase III trial. Lancet 2009; 373: 301. 139. Albertsen PC, Hanley JA, Gleason DF et al: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975. 140. Abdollah F, Sun M, Schmitges J et al: Competing risks mortality after radiotherapy vs. observation for localized prostate cancer: a population based study. Int J Radiat Oncol Biol Phys 2012; 84: 95. 141. Chin JL , Al Zahrani AA , Autran Gomez AM et al: Extended followup oncologic outcome of randomized trial between cryoablation and external beam therapy for locally advanced prostate cancer (T2c T3b). J Urol 2012: 188:1170. 142. Thomsen FB, Brasso K, Christensen IJ et al: Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long term follow up of the SPCG 6 study. Eur J Cancer 2015; 51:1283. 143. Potosky AL, Haque R, Cassidy Bushrow AE et al: Effectiveness of primary androgen deprivation therapy for clinically localized prostate cancer. J Clin Oncol 2014; 32: 1324. 144. Lu Yao GL, Albertson PC, Moore DF et al: Survival following primary androgen deprivation therapy among men with localized prostate cancer JAMA 2008;300:173. 145. Lu Yao GL, Albertson PC, Moore DF et al: Fifteen year survival outcomes following primary androgen deprivation therapy for localized prostate cancer. JAMA Intern Med 2014; 174:1460. 146. Kote Jarai Z, Leongamornlert D, Saunders E et al: BRCA2 is a moderate penetrance gene contributing to young onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011; 105: 1230. 147. Gallagher DJ, Gaudet MM, Pal P et al: Germline BRCA mutations denote a clinicopathologic subset American Urological Association (AUA) / American Society for Radiation Oncology (ASTRO) / Society of Urologic Oncology (SUO) Copyright © 2017 American Urological Association Education and Research, Inc.® Clinically Localized Prostate Cancer 48 of prostate cancer. Clin Cancer Res 2010; 16: 2115. 148. Robinson D, Van Allen EM, Wu YM et al: Integrative clinical genomics of advanced prostate cancer. Call 2015; 161: 1215. 149. Pritchard CC, Mateo J, Walsh MF et al: Inherited DNA repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016; 375: 443. 150. Chun FK, Epstein JI, Ficarra V, et al. Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature. Eur Urol 2010; 58:851. 151. NCCN Guidelines: Prostate cancer early detection [v.2.2012]. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. 152. Heidenreich A, Bellmunt J, Bolla M et al: EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59:61. 153. Wright JL and Ellis WJ: Improved prostate cancer detection with anterior apical prostate biopsies. Urol Oncol 2006; 24: 492. 154. Scattoni V, Zlotta A, Montironi R et al: Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007; 52:1309. 155. Scattoni V, Zlotta AR, Nava L et al: Prostatic transrectal ultrasound (TRUS) guided biopsy schemes and TRUS prostatic lesion guided biopsies. Eur Urol Suppl 2002;1(6):28. 156. Remzi M, Fong YK, Dobrovits M et al: The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 2005; 174:1256. 157. Eichler K, Hempel S, Wilby J et al: Diagnostic value of systematic biopsy methods in the investiga tion of prostate cancer: a systematic review. J Urol 2006; 175: 1605. 158. Jones JS, Patel A, Schoenfield L et al: Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol 2006; 175:485. 159. Onik G, Miessau M and Bostwick DG: Three dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol 2009; 27:4321. 160. Ahmed HU, Hu Y, Carter T et al: Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol 2011; 186:458. 161. Itatani R, Namimoto T, Atsuji et al: Negative predictive value of multiparametric MRI for prostate cancer detection: Outcome of 5 year follow up in men with negative findings on initial MRI studies. Eur J Radiol 2014; 83: 1740. 162. Pokorny MR, de Rooij M, Duncan E et al: Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound guided biopsy versus magnetic resonance (MR) imaging with subsequent MR guided biopsy in men without previous prostate biopsies. Eur Urol 2014; 66: 22. 163. Wysock JS, Mendhiratta N, Zattoni F et al: Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12 core biopsy results. BJU Int 2016; 118: 515. 164. Walton Diaz A, Shakir NA, George AK et al: Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. Urol Oncol 2015;33:202. 165. Rais Bahrami S, Türkbey B, Rastinehad AR et al: Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow up. Diagn Interv Radiol 2014; 20:293. 166. Okotie OT, Roehl KA, Han M et al: Characteristics of prostate cancer detected by digital rectal examination only. Urology 2007;70:1117. 167. Bul M, Zhu X, Valdagni R et al: Active surveillance for low risk prostate cancer worldwide: the PRIAS study. Eur Urol 2013; 63:597 168. Dall'Era MA, Konety BR, Cowan JE et al: Active surveillance for the management of prostate cancer in